A study of smoking, p53 tumor suppressor gene alterations and non-small cell lung cancer

Annals of Epidemiology

Volumn 10, Issue 3, 2000, Pages 176-185

  Tammemagi, Martin C ^a   Mclaughlin, John R ^b   Mullen, J Brendan M ^c   Bull, Shelley B ^b   Johnston, Michael R ^d   Tsao, Ming Sound ^d   Casson, Alan G ^e  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Immunohistochemistry; Lung Cancer; p53 Tumor Suppressor Gene; Smoking

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ODDS RATIO; ONTARIO; PROSPECTIVE STUDIES; SMOKING; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034175926     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(99)00048-4     Document Type: Article

References (85)

1. Cancer Facts & Figures-1998. Atlanta, GA: American Cancer Society, Inc.; 1998.
2. Shopland D.R., Eyre H.J., Pechacek T.F. Smoking-attributable cancer mortality in 1991. Is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst. 83(16):1991;1142-1148.
3. Travis W.D., Lubin J., Ries L., Devesa S. United States lung carcinoma incidence trends. Declining for most histologic types among males, increasing among females Cancer. 77(12):1996;2464-2470.
4. Devesa S.S., Blot W.J., Stone B.J., Miller B.A., Tarone R.E., Fraumeni J.F. Jr. Recent cancer trends in the United States. J Natl Cancer Inst. 87(3):1995;175-182.
5. Siemiatycki J., Krewski D., Franco E., Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer. A multi-site case-control study Intl J Epidemiol. 24(3):1995;504-514.
6. Devereux T.R., Taylor J.A., Barrett J.C. Molecular mechanisms of lung cancer. Interaction of environmental and genetic factors. Giles F. Filley Lecture. Chest. 109(suppl 3):1996;S14-S19.
7. Tammemagi M.C., McLaughlin J.R., Bull S.B. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathologic features in resected lung cancer. Cancer Epidemiol Biomark Prev. 8(7):1999;625-634.
8. Harris C.C. Structure and function of the p53 tumor suppressor gene. Clues for rational cancer therapeutic strategies J Natl Cancer Inst. 88(20):1996;1442-1455.
9. Kobzik L. The lung. Cotran R., Kumar V., Collins T. Robbins Pathologic Basis of Disease. 6th ed:1999;697-755 W.B. Saunders Company, Philadelphia.
10. Hall P.A., Lane D.P. p53 in tumour pathology. Can we trust immunohistochemistry?Revisited! J Pathol. 172(1):1994;1-4.
11. Feld R., Abratt R., Graziano S., Jassem J., Lacquet L., Ninane V.et al. Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer. 17(suppl 1):1997;S3-S10.
12. Graziano S.L. Non-small cell lung cancer. clinical value of new biological predictors Lung Cancer. 17(suppl 1):1997;S37-S58.
13. Hinds M.W., Yang H.Y., Stemmermann G., Lee J., Kolonel L.N. Smoking history and lung cancer survival in women. J Natl Cancer Inst. 68(3):1982;395-399.
14. Goodman M.T., Kolonel L.N., Wilkens L.R., Yoshizawa C.N., Le Marchand L. Smoking history and survival among lung cancer patients. Cancer Causes Control. 1(2):1990;155-163.
15. Sobue T., Suzuki T., Fujimoto I., Doi O., Tateishi R., Sato T. Prognostic factors for surgically treated lung adenocarcinoma patients, with special reference to smoking habit. Jpn J Cancer Res. 82(1):1991;33-39.
16. Richardson G.E., Tucker M.A., Venzon D.J., Linnoila R.I., Phelps R., Phares J.C.et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Int Med. 119(5):1993;383-390.
17. Isobe T., Hiyama K., Yoshida Y., Fujiwara Y., Yamakido M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res. 85(12):1994;1240-1246.
18. Xavier F., Henn LdA Oliveira M., Oriandine L. Smoking and its relation to the histological type, survival, and prognosis among patients with primary lung cancer. Rev Paul Med. 114:1996;1298-1302.
19. Fujisawa T., Shiba M., Baba M., Lizasa T., Suitoh Y., Yamaguchi Y.et al. Smoking before surgery predicts poor long-term survival in stage I nonsmall cell lung carcinoma. Lung Cancer. 18(suppl):1997;95.
20. Linden G., Dunn J.E. Jr., Hom P.H., Mann M. Effect of smoking on the survival of patients with lung cancer. Cancer. 30(2):1972;325-328.
21. Shimizu H., Tominaga S., Nishimura M., Urata A. Comparison of clinico-epidemiological features of lung cancer patients with and without a history of smoking. Jpn J Clin Oncol. 14(4):1984;595-600.
22. Morkve O., Halvorsen O.J., Skjaerven R., Stangeland L., Gulsvik A., Laerum O.D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res. 13(3):1993;571-578.
23. Ebina M., Steinberg S.M., Mulshine J.L., Linnoila R.I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54(9):1994;2496-2503.
24. Harpole D.H. Jr., Herndon J.E. 2nd, Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55(1):1995;51-56.
25. Wu-Williams A.H., Samet J.M. Lung cancer and cigarette smoking. Samet J.M. Epidemiology of Lung Cancer. 1994;71-108 Marcel Dekker, New York.
26. The World Health Organization histological typing of lung tumours Second edition. Am J Clin Pathol. 77(2):1982;123-136.
27. Beahrs OH, American Joint Committee on Cancer. American Cancer Society. Manual for staging of cancer. 3rd ed. Philadelphia: Lippincott; 1988.
28. Beahrs OH, American Joint Committee on Cancer. American Cancer Society. Manual for staging of cancer. 4th ed. Philadelphia: Lippincott; 1992.
29. Casson A.G., Tammemagi M., Eskandarian S., Redston M., McLaughlin J., Ozcelik H. p53 alterations in esophageal cancer. Association with clinicopathologic features, risk factors and survival J Clin Pathol: Mol Pathol. 51:1998;71-79.
30. Casson A.G., McCuaig S., Craig I., Ayed A., Inculet R., Kerkvliet N.et al. Prognostic value and clinicopathologic correlation of p53 gene mutations and nuclear DNA content in human lung cancer. A prospective study J Surg Oncol. 56(1):1994;13-20.
31. Allred D.C., Clark G.M., Elledge R., Fuqua S.A., Brown R.W., Chamness G.C.et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 85(3):1993;200-206.
32. Fleiss J.L. The Design and Analysis of Clinical Experiments. 1986;Wiley, New York.
33. Parmar MKB, Machin D. Survival Analysis: A Practical Approach. Chichester, NY: J. Wiley; 1995.
34. Kaplan D., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
35. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22:1959;719-748.
36. Cox D. Regression models and life tables. J R Stat Soc. 34:1972;187-220.
37. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 79(3):1989;340-349.
38. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester, NY: J. Wiley; 1995.
39. Allison P.D., SAS Institute Survival Analysis Using the SAS System. A Practical Guide:1995;SAS Institute, Cary, NC.
40. Chiba I., Takahashi T., Nau M.M., D'Amico D., Curiel D.T., Mitsudomi T.et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 5(10):1990;1603-1610.
41. Hiyoshi H., Matsuno Y., Kato H., Shimosato Y., Hirohashi S. Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res. 83(1):1992;101-106.
42. Fujino M., Dosaka-Akita H., Harada M., Hiroumi H., Kinoshita I., Akie K.et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer. 76(12):1995;2457-2463.
43. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Ueda R. p53 mutations in non-small cell lung cancer in Japan. Association between mutations and smoking Cancer Res. 52(3):1992;734-736.
44. Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I.et al. p53 mutations in lung tumors. Relationship to putative susceptibility markers for cancer Cancer Res. 54(6):1994;1551-1555.
45. Kondo K., Tsuzuki H., Sasa M., Sumitomo M., Uyama T., Monden Y. A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol. 61(1):1996;20-26.
46. Gosney J.R., Butt S.A., Gosney M.A., Field J.K. Exposure to cigarette smoke and expression of the protein encoded by the p53 gene in bronchial carcinoma. Ann N Y Acad Sci. 686:1993;243-248.
47. Westra W.H., Offerhaus G.J., Goodman S.N., Slebos R.J., Polak M., Baas I.O.et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 17(3):1993;213-220.
48. Dosaka-Akita H., Shindoh M., Fujino M., Kinoshita I., Akie K., Katoh M.et al. Abnormal p53 expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am J Clin Pathol. 102(5):1994;660-664.
49. Esposito V., Baldi A., De Luca A., Micheli P., Mazzarella G., Baldi F.et al. Prognostic value of p53 in non-small cell lung cancer. Relationship with proliferating cell nuclear antigen and cigarette smoking Hum Pathol. 28(2):1997;233-237.
50. McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K.C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer. 66(4):1992;735-738.
51. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52(17):1992;4828-4831.
52. Volm M., Efferth T., Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res. 12(1):1992;11-20.
53. Brambilla E., Gazzeri S., Moro D., Caron de Fromentel C., Gouyer V., Jacrot M.et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol. 143(1):1993;199-210.
54. Lee L.N., Shew J.Y., Sheu J.C., Lee Y.C., Lee W.C., Fang M.T.et al. Exon 8 mutation of p53 gene associated with nodal metastasis in non- small-cell lung cancer. Am J Respir Crit Care Med. 150(6 Pt 1):1994;1667-1671.
55. Li Z.H., Zheng J., Weiss L.M., Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol. 144(2):1994;303-309.
56. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A.et al. Bcl-2 protein. A prognostic factor inversely correlated to p53 in non- small-cell lung cancer Br J Cancer. 71(5):1995;1003-1007.
57. Kashii T., Mizushima Y., Lima C.E., Noto H., Sato H., Saito H.et al. Studies on clinicopathological features of lung cancer patients with K- ras/p53 gene alterations. Comparison between younger and older groups Oncology. 52(3):1995;219-225.
58. Top B., Mooi W.J., Klaver S.G., Boerrigter L., Wisman P., Elbers H.R.et al. Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer. Int J Cancer. 64(2):1995;83-91.
59. Kwa H.B., Michalides R.J., Dijkman J.H., Mooi W.J. The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. Lung Cancer. 14(2-3):1996;207-217.
60. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T.et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53(1):1993;1-4.
61. Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 85(24):1993;2018-2023.
62. Xu H.J., Quinlan D.C., Davidson A.G., Hu S.X., Summers C.L., Li J.et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 86(9):1994;695-699.
63. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N.et al. Expression of p53 oncoprotein in non-small-cell lung cancer. A favorable prognostic factor J Clin Oncol. 13(8):1995;1893-1903.
64. Passlick B., Izbicki J.R., Haussinger K., Thetter O., Pantel K. Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg. 109(6):1995;1205-1211.
65. Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S.et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 7(1):1992;171-180.
66. Nishio M., Koshikawa T., Kuroishi T., Suyama M., Uchida K., Takagi Y.et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol. 14(2):1996;497-502.
67. de Juan C., Iniesta P., Vega F.J., Peinado M.A., Fernandez C., Caldes T.et al. Prognostic value of genomic damage in non-small-cell lung cancer. Br J Cancer. 77(11):1998;1971-1977.
68. Thomas W.R., Holt P.G., Keast D. Development of alterations in the primary immune response of mice by exposure to fresh cigarette smoke. Intl Arch Allergy Appl Immunol. 46(4):1974;481-486.
69. Thomas W.R., Holt P.G., Keast D. Recovery of immune system after cigarette smoking. Nature. 248(446):1974;358-359.
70. Chalmer J., Holt P.G., Keast D. Cell-mediated immune responses to transplanted tumors in mice chronically exposed to cigarette smoke. J Natl Cancer Inst. 55(5):1975;1129-1134.
71. Berg J.W., Ross R., Latourette H.B. Economic status and survival of cancer patients. Cancer. 39(2):1977;467-477.
72. Nomura A., Kolonel L., Rellahan W., Lee J., Wegner E. Racial survival patterns for lung cancer in Hawaii. Cancer. 48(5):1981;1265-1271.
73. Holmes E. Staging Non-Small Cell Lung Cancer. 1990;Bristol-Meyers Squibb Co, Evansville, IN.
74. Minna J. Neoplasms of the lung. Wilson J., Braunwald E., Isselbacher K., Petersdorf R., Martin J., Fauci A.et al. Harrison's Principles of Internal Medicine. 12th ed:1991;McGraw-Hill Inc, New York.
75. Dalquen P., Sauter G., Torhorst J., Schultheiss E., Jordan P., Lehmann S.et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol. 178(1):1996;53-58.
76. Charloux A., Hedelin G., Dietemann A., Ifoundza T., Roeslin N., Pauli G.et al. Prognostic value of histology in patients with non-small cell lung cancer. Lung Cancer. 17(1):1997;123-134.
77. McLaughlin JR, Sloan MR, Janovjak DP, Ontario Cancer Registry. Ontario Cancer Treatment and Research Foundation. Cancer survival in Ontario. Toronto, Canada: Ontario Cancer Treatment and Research Foundation; 1995.
78. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer. 75(suppl 1):1995;191-202. [published erratum appears in Cancer 1995 Jun 15;75(12):2979].
79. Wynder E.L., Muscat J.E. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect. 103(suppl 8):1995;143-148.
80. Hoffmann D., Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health. 50(4):1997;307-364.
81. Altman D.G. Categorising continuous variables. Br J Cancer. 64(5):1991;975.
82. Cantor A.B., Shuster J.J. Re. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst. 86(23):1994;1798-1799.
83. Langendijk J.A., Thunnissen F.B., Lamers R.J., de Jong J.M., ten Velde G.P., Wouters E.F. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol. 36(3):1995;218-224.
84. Barnes D.M., Hanby A.M., Gillett C.E., Mohammed S., Hodgson S., Bobrow L.G.et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet. 340(8814):1992;259-263.
85. Birch J.M., Heighway J., Teare M.D., Kelsey A.M., Hartley A.L., Tricker K.J.et al. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer. 70(6):1994;1176-1181.